ReviewMolecular biotechnology2026
Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Dual-system engineered bacteria and dendritic cells enable precise intratumoral IL-12 delivery and potent antitumor immunity.Cell reports. Medicine · 2026Article
- p21 Knockdown as a Therapeutic Strategy for Focal Cartilage Injury Repair.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond.Nanoscale advances · 2026Review
- Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer.Cancers · 2026Article
- An AAV-Based Therapy Approach for Neurological Phenotypes of X-Linked Adrenoleukodystrophy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Since their development in the 1990s, the applications of lentiviral vectors have rapidly extended to the fields of gene and cancer therapy, as well as vaccine development, owing to their unique advantages of efficiently transducing both dividing and nondividing cells and achieving stable and long-term expression of genes. However, with their clinical application, potential safety issues have emerged, such as the possibility of insertional oncogenesis, immune reactions, and tumorigenesis, which have attracted widespread attention from the academic and clinical communities. In this review, we thoroughly explore the strategies used to optimize lentiviral vectors and assess their potential benefits and risks in different fields. We summarize the latest research on the use of lentiviral vectors, covering their development, classification, and applications in cancer therapy, treatment of genetic diseases, and vaccine development, as well as discussing important safety considerations. This review acts as an informative reference for academics and clinicians, providing insights into the potential future research directions and possible clinical applications of lentiviral vectors. We hope that this review will promote the continuous improvement of lentiviral vector technology and realize its full therapeutic potential in the treatment and prevention of diseases.
Indexed as
Identifiers
40617903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.